ERCC1-Expression unter 5-FU- und Oxaliplatin-basierter multimodaler Therapie beim Rektumkarzinom (cUICC-Stadien II und III) - Potentielle prädiktive und prognostische Bedeutung

Gauß, Korbinian Andreas

dc.contributor.advisor	Conradi, Lena-Christin Dr.
dc.contributor.author	Gauß, Korbinian Andreas
dc.date.accessioned	2014-05-19T14:21:32Z
dc.date.available	2014-06-03T22:50:04Z
dc.date.issued	2014-05-19
dc.identifier.uri	http://hdl.handle.net/11858/00-1735-0000-0022-5EBB-B
dc.identifier.uri	http://dx.doi.org/10.53846/goediss-4512
dc.language.iso	deu	de
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/3.0/
dc.subject.ddc	610	de
dc.title	ERCC1-Expression unter 5-FU- und Oxaliplatin-basierter multimodaler Therapie beim Rektumkarzinom (cUICC-Stadien II und III) - Potentielle prädiktive und prognostische Bedeutung	de
dc.type	doctoralThesis	de
dc.title.translated	ERCC1 expression under 5-FU and oxaliplatin-based multimodal treatment in rectal cancer (cUICC II and III) - Potential predictive and prognostic impact	de
dc.contributor.referee	Liersch, Torsten Prof. Dr.
dc.date.examination	2014-05-27
dc.description.abstracteng	Purpose:The application of neoadjuvant radiochemotherapy (RCT) improves local control of patients with advanced rectal cancer. Current clinical trials focus on therapy intensification (e.g. using oxaliplatin) and the investigation of predictive and prognostic biomarkers. In this regard, the ERCC1 expression was investigated in UICC-II/-III rectal cancer patients. Patients and Methods: The study included 211 rectal cancer patients (148 male, 63 female; median age 63 years). All patients received standardized multimodal treatment using 5-FU (n=138) or 5-FU in combination with Oxaliplatin (n=73). ERCC1 expression was determined in pretherapeutical tumor biopsies and resection specimens using immunohistochemistry. The results were correlated with clinicopathological parameters [e.g. tumorregression grade (TRG), postoperative nodal-status (ypN)] and long-term survival. Results: ERCC1 expression was significantly lower in resection specimens compared to pretherapeutical tumor tissue (p<0,05). The pretherapeutical expression showed no correlation with clinicopathological response. High pretherapeutical ERCC1 expression was associated with an increased rate of local recurrences (p=0,031). Conclusion: ERCC1 expression appeared as a potential prognostic biomarker in advanced rectal cancer and should therefore be validated and further investigated in prospective clinical trials.	de
dc.contributor.coReferee	Wolff, Hendrik PD Dr.
dc.subject.ger	ERCC1	de
dc.subject.ger	Rektumkarzinom	de
dc.subject.ger	Kolorektales Karzinom	de
dc.subject.ger	Oxaliplatin	de
dc.subject.eng	rectal cancer	de
dc.subject.eng	ercc1	de
dc.subject.eng	oxaliplatin	de
dc.subject.eng	colorectal cancer	de
dc.subject.eng	ERCC1	de
dc.identifier.urn	urn:nbn:de:gbv:7-11858/00-1735-0000-0022-5EBB-B-8
dc.affiliation.institute	Medizinische Fakultät	de
dc.subject.gokfull	GOK-MEDIZIN	de
dc.description.embargoed	2014-06-03
dc.identifier.ppn	786012137

Dateien

Name:DISSERTATION_KORBINIAN_GAUSS_web5.pdf

Größe:2.591Mb

Format:PDF

Öffnen

Name:: DISSERTATION_KORBINIAN_GAUSS_w ...
Größe:: 2.591Mb
Format:: PDF

Öffnen

Das Dokument erscheint in:

Human- und Zahnmedizin [2872]

Zur Kurzanzeige